Imaging endpoints for non-alcoholic steatohepatitis (NASH) therapeutic trials: A growing role for multiparametric MRI?

J Hepatol. 2018 Sep;69(3):755-756. doi: 10.1016/j.jhep.2018.04.022. Epub 2018 May 16.

Authors

Rajarshi Banerjee¹, Matthew Kelly², Henry Wilman³, Teresa Wright⁴, Stefan Neubauer⁵

Affiliations

¹ Perspectum Diagnostics, Oxford, UK.
² Perspectum Diagnostics, Oxford, UK. Electronic address: matt.kelly@perspectum-diagnostics.com.
³ Perspectum Diagnostics, Oxford, UK; University of Westminster, London, UK.
⁴ Department of Medicine, University of California, San Francisco, USA.
⁵ Perspectum Diagnostics, Oxford, UK; Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, UK.

PMID: 29778300
DOI: 10.1016/j.jhep.2018.04.022

No abstract available

Keywords: Cardiovascular; Liver; MRI; NAFLD; NASH.

Publication types

Letter
Comment

MeSH terms

Humans
Magnetic Resonance Imaging
Non-alcoholic Fatty Liver Disease*